Glycemic Effectiveness of Metformin-Based Dual-Combination Therapies with Sulphonylurea, Pioglitazone, or DPP4-Inhibitor in Drug-Naïve Korean Type 2 Diabetic Patients

This study compared the glycemic effectiveness of three metformin-based dual therapies according to baseline hemoglobin A1c (HbA1c) to evaluate the appropriateness of the guideline enforced by the National Health Insurance Corporation of Korea for initial medication of type 2 diabetes (T2D). This pr...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes & metabolism journal 2013, 37(6), 140, pp.465-474
Main Authors: Lee, Young Ki, Song, Sun Ok, Kim, Kwang Joon, Cho, Yongin, Choi, Younjeong, Yun, Yujung, Lee, Byung-Wan, Kang, Eun-Seok, Cha, Bong Soo, Lee, Hyun Chul
Format: Article
Language:English
Subjects:
Diabetes mellitus, type 2
Metformin
Original
Pioglitazone
Sitagliptin
Sulphonylurea
내과학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study compared the glycemic effectiveness of three metformin-based dual therapies according to baseline hemoglobin A1c (HbA1c) to evaluate the appropriateness of the guideline enforced by the National Health Insurance Corporation of Korea for initial medication of type 2 diabetes (T2D). This prospective observational study was conducted across 24 weeks for drug-naïve Korean T2D patients with HbA1c greater than 7.5%. Subjects were first divided into three groups based on the agent combined with metformin (group 1, gliclazide-modified release or glimepiride; group 2, pioglitazone; group 3, sitagliptin). Subjects were also classified into three categories according to baseline HbA1c (category I, 7.5%≤HbA1c
ISSN:2233-6079
2233-6087
DOI:10.4093/dmj.2013.37.6.465